Presentation description

Despite advancements in the respiratory management of neonates, bronchopulmonary dysplasia (BPD; also known as neonatal chronic lung disease) remains absent of any definitive treatment options. AVR-48 is a novel immunomodulatory molecule derived from chitohexaose, an essential structural component responsible for the pathogen immune responses of filarial parasites. We hypothesized that AVR-48 will improve early outcomes of preterm lambs that are mechanically ventilated for 7d. Lung function was measured in terms of respiratory severity score, saturation/FiO2 (S/F) ratio, PaO2/FiO2 (P/F) ratio, oxygenation index, Aterial-alveolar oxygen (A-a) gradient, resistance (R), dynamic compliance (Cdyn), as well as structural indices.